Acetonitrile Market

How big is Acetonitrile Market in 2026?

USD 510.8 million in 2026 and USD 989.0 million by 2036 at a 6.8% CAGR.

Demand for acetonitrile is projected to expand at a 6.8% CAGR between 2026 and 2036. Valuation is expected to rise from USD 510.8 million to USD 989.0 million as high purity solvents gain importance in regulated analysis. MilliporeSigma launched a bio-based HPLC acetonitrile in April 2026 for established HPLC and LC-MS methods. The launch strengthens premium-grade purchasing by letting laboratories change solvent sourcing without redeveloping validated analytical methods.

National pharmaceutical workloads produce different purchasing conditions even though acetonitrile serves the same analytical function. BfArM counted 103,678 marketable medicinal products in Germany during December 2025, which sustains extensive release and quality-control activity around pharmaceutical solvents. Brazil’s public industrial policy is expanding domestic medicine production and increases the importance of reliable imported solvent inputs during localization. Producers therefore plan inventory differently: Germany emphasizes continuity within a mature medicine base while Brazilian projects need dependable supply during manufacturing expansion.

Key Takeaways of Acetonitrile Market

• Regulated analytical testing and pharmaceutical synthesis require acetonitrile grades with controlled impurities and documented lot consistency.
• Specialty grade is estimated to hold 61.3% of product-type demand in 2026 because HPLC and synthesis workflows are sensitive to solvent-quality variation.
• Pharmaceuticals & biotechnology is expected to lead end user industry with 37.9% share in 2026 because synthesis and quality-control laboratories use acetonitrile repeatedly.
• Other product grades together account for the remaining 38.7% in 2026 since broader chemical processing tolerates specifications below specialty-grade requirements.
• Co-product-linked production and solvent recovery can reduce merchant demand or tighten availability even while analytical and pharmaceutical workloads continue expanding.
• Some of the key players in this market include INEOS Nitriles, Ascend Performance Materials, Merck KGaA, Solstice Advanced Materials, Thermo Fisher Scientific, Asahi Kasei Corporation, Balaji Amines Limited, and Alkyl Amines Chemicals Limited.

Analyst Perspective

"Acetonitrile purchasing should be evaluated against method sensitivity and replenishment risk before teams compare the nominal solvent price. Commercial value rises for producers controlling purification and documentation while distributors preserve lot integrity during the customer qualification cycle."

- Nikhil Kaitwade, Principal Consultant, Future Market Insights

How is the Acetonitrile Market segmented?

The acetonitrile market is segmented by product type and end user industry, with regional analysis applied to both categories.

Product type includes specialty grade, laboratory grade, and industrial grade. End user industry includes pharmaceuticals & biotechnology, chemical industry, laboratories & analytical services, electronics & energy, and others.

Why does Pharmaceuticals & Biotechnology lead the End User Industry category?

Pharmaceutical manufacturers use acetonitrile during synthesis and purification. Laboratories then consume it with chromatography instrumentation in release testing. FDA recorded 689 ANDA approvals during FY2025, sustaining repeated quality-control work for marketed generic products. Adjacent purification workflows also use chromatography resins within the same biopharmaceutical facilities without determining the approved acetonitrile share.

• In 2026, pharmaceuticals & biotechnology is expected to lead end user industry with 37.9% share since acetonitrile enters both manufacturing and analytical workflows.
• Drug manufacturers prefer material that can pass validated specifications without repeated method investigation, which raises the commercial value of consistent high-purity supply.

What makes Specialty Grade central to the Product Type category?

Specialty grade serves analytical methods in which water content and trace impurities affect baseline stability or detection limits. Laboratories qualify solvent performance beside chromatography reagents during routine adoption. Ascend Performance Materials opened its Chocolate Bayou recovery and purification facility in February 2026. The plant serves pharmaceutical manufacturing and analytical laboratories with high-purity material that still requires lot-level qualification.

• By product type, specialty grade is estimated to hold 61.3% in 2026 owing to tighter impurity limits in pharmaceutical and analytical workflows.
• Laboratories select qualified specialty material to protect method transfer and repeatability, while routine chemical processing can use grades with broader impurity tolerances.

What are the drivers, restraints and opportunities in the Acetonitrile Market?

Drug manufacturing and chromatography increase qualified demand, solvent recovery and co-product economics limit merchant purchases, and battery applications provide a separate specialty route.

• Driver: Pharmaceutical development and quality-control testing increase demand for qualified acetonitrile used in synthesis, purification, HPLC, and LC-MS workflows.
• Restraint: Closed-loop solvent recovery and dependence on acrylonitrile operating rates can reduce fresh purchases while raising supply risk during production disruptions.
• Opportunity: Acetonitrile-containing electrolytes give chemical producers a route into high-power batteries where ionic conductivity can justify application-specific formulations.

Regulated testing converts pharmaceutical activity into repeat solvent consumption as validated methods require consistent mobile-phase behavior from development to commercial release. FDA approved 46 novel drugs during 2025, expanding the set of products that enter analytical method development and later routine quality control. Laboratories also consume chromatography consumables during those workflows, so acetonitrile producers gain higher-value demand where purity records reduce investigations around solvent background or trace contaminants.

Solvent recovery changes purchase economics at validated plants since reused material displaces part of each fresh acetonitrile order. Biocon reported during FY2025 that its Malaysia facility recovered spent acetonitrile and reduced fresh consumption by about 140 tons per month. Recovery investment therefore limits merchant volume at efficient plants and raises demand for solvent dehydration chemicals that help return recovered streams to controlled process specifications.

Battery developers offer a route beyond conventional solvent demand by using acetonitrile inside electrolytes designed for high ionic conductivity and rapid discharge. Asahi Kasei licensed its acetonitrile-containing Acetolyte technology to EAS Batteries in November 2025 for an ultra-high-power LFP cell. Producers can pursue this application beside demand from LC-MS/MS systems while maintaining separate formulation controls since pharmaceutical solvents and battery electrolytes require different qualification evidence.

Which country CAGRs are profiled in the Acetonitrile Market?

Country	CAGR
Brazil	7.6%
India	7.6%
China	7.2%
United States	6.4%
Germany	5.8%

How do country-level CAGRs compare in the Acetonitrile Market?

The profiled countries span 1.8 percentage points between Brazil and India at 7.6% and Germany at 5.8%. Brazil and India form the upper-growth group, followed by China at 7.2%, while the United States and Germany record comparatively slower rates. The spacing reflects differences in pharmaceutical manufacturing, analytical testing, and domestic chemical supply conditions rather than current market size alone, so similar growth rates can lead to different account priorities.

• Brazil links its higher rate to policies supporting domestic pharmaceutical production and local health-industry capacity.
• India combines expanding pharmaceutical manufacturing with government-backed investment in APIs, drug intermediates, and high-value medicines.
• China benefits from continued pharmaceutical innovation and faster regulatory pathways that support drug-development and analytical testing activity.
• United States laboratories benefit from established pharmaceutical and analytical infrastructure alongside domestic solvent recovery and purification capabilities.
• Germany faces a more mature pharmaceutical market where supply continuity and validated solvent sourcing remain important purchasing considerations.

Comparable growth rates therefore produce different inventory and qualification priorities for producers serving regulated accounts.

The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• Public health procurement and industrial policy increasingly support domestic pharmaceutical production, strengthening the local manufacturing base and associated analytical testing requirements. In July 2026, Brazil established the National Strategy for the Health Economic-Industrial Complex, creating a permanent policy framework to strengthen domestic development, production, and innovation in medicines, vaccines, and other health technologies. Acetonitrile demand in Brazil is forecast to rise at 7.6% CAGR through 2036, supported by pharmaceutical manufacturing and the analytical workload associated with drug development and quality control. Import-dependent solvent supply can still expose pharmaceutical sites to logistics and customs-related delays, increasing the value of qualified regional inventory and reliable documentation.
• Expanding domestic pharmaceutical manufacturing is supporting demand for analytical solvents used in drug development, quality control, and formulation testing. Government Production Linked Incentive schemes are strengthening domestic production of pharmaceuticals, APIs, drug intermediates, and key starting materials; by December 2025, the pharmaceutical PLI scheme had generated ₹41,943 crore in cumulative investment, while 726 APIs/KSMs/DIs were being manufactured under the scheme. The Indian acetonitrile market is projected to record 7.6% CAGR through 2036, supported by pharmaceutical manufacturing expansion and associated laboratory testing. Growing production capacity increases recurring demand for high-purity solvents, while regulated laboratories continue to require consistent quality, certificates, and qualified sources.
• China's pharmaceutical innovation pipeline and evolving regulatory framework are sustaining analytical activity across drug development and quality testing. The National Medical Products Administration introduced a pathway allowing eligible innovative-drug clinical trial applications to be reviewed within 30 working days, supporting faster clinical development. China also approved 48 first-in-class innovative drugs in 2024, the highest number in five years, highlighting the scale of ongoing pharmaceutical development. Acetonitrile demand in China is forecast to expand at 7.2% CAGR through 2036, supported by pharmaceutical R&D, quality-control testing, and high-purity solvent requirements. Producers with dependable local supply and strong technical documentation can benefit as laboratories scale testing activity and maintain validated analytical methods.
• Established pharmaceutical manufacturing and laboratory infrastructure continues to support recurring demand for high-purity acetonitrile across analytical testing, quality control, and drug-development applications. The United States is estimated to post 6.4% CAGR through 2036, supported by pharmaceutical research activity and established analytical-solvent consumption. Domestic recovery and purification capacity can shorten supply routes for laboratories, but hazardous-material handling, lot-release requirements, and validated analytical methods continue to make consistency and documentation important. Producers that combine reliable domestic availability with consistent certificates of analysis and compliant packaging can strengthen relationships with regulated laboratory customers.
• Germany's mature pharmaceutical and chemical industries sustain demand for acetonitrile in pharmaceutical quality control, chromatography, and research applications, although growth is comparatively slower than in emerging pharmaceutical manufacturing markets. Germany's acetonitrile market is anticipated to advance at 5.8% CAGR through 2036, reflecting its established pharmaceutical base and mature laboratory infrastructure. Supply continuity remains important because validated analytical methods can make solvent-source changes costly and time-consuming. Producers with dependable regional inventory, consistent lot quality, and complete documentation can therefore support account retention among regulated pharmaceutical and laboratory users.

Who are the notable companies in the Acetonitrile Market?

INEOS Nitriles, Ascend Performance Materials, Merck KGaA, Solstice Advanced Materials, Thermo Fisher Scientific, Asahi Kasei Corporation, Balaji Amines Limited, and Alkyl Amines Chemicals Limited are the notable companies serving this market.

Competition separates acetonitrile producers from laboratory brands controlling qualified customer access. INEOS and Ascend hold upstream positions, while Merck and Solstice sell specialized grades beside process chromatography workflows. Thermo Fisher serves analytical laboratories with certified solvents. Asahi Kasei extends acetonitrile into batteries, while Balaji Amines and Alkyl Amines retain Indian manufacturing positions influenced by trade measures and capacity investment.

• Integrated production platforms include INEOS Nitriles, Ascend Performance Materials, Balaji Amines Limited, and Alkyl Amines Chemicals Limited.
• Laboratory-grade channels include Merck KGaA, Solstice Advanced Materials, and Thermo Fisher Scientific for chromatography and regulated analytical work.
• Asahi Kasei Corporation spans merchant acetonitrile supply and application development around acetonitrile-containing battery electrolytes.

Competitive Benchmarking: Acetonitrile Market

Company	Supply Control	Chromatography-Grade Breadth	Application Depth	Geographic Reach
INEOS Nitriles	High	High	Medium	North America, Europe, and Asia
Ascend Performance Materials	High	Medium	High	North America and export channels
Merck KGaA	Low	High	High	Global life-science distribution
Solstice Advanced Materials	Low	High	High	North America, Europe, and Asia
Thermo Fisher Scientific	Low	High	Medium	Global scientific distribution
Asahi Kasei Corporation	High	Low	High	Japan, South Korea, China, and global customers
Balaji Amines Limited	High	Medium	Medium	India with international sales
Alkyl Amines Chemicals Limited	High	Low	Medium	India with export customers

Scoring basis: High supply control requires documented production or recovery assets while Medium requires narrower controlled capacity and Low identifies distribution-led supply. High chromatography breadth requires multiple analytical grades while Medium requires one dedicated route and Low identifies no dedicated chromatography breadth. High application depth requires three documented use groups while Medium requires two and Low identifies one.

Key Developments in the Acetonitrile Market

• In August 2026, Asahi Kasei Corporation signed a license agreement with HighChem Shanghai for local production and sale of its acetonitrile-containing Acetolyte electrolyte in China.
• In October 2025, Solstice Advanced Materials completed its spin-off from Honeywell and retained the Research & Performance Chemicals business serving chromatography-solvent customers.
• In June 2025, Balaji Amines Limited disclosed an upgrade of its Chincholi acetonitrile plant toward 60 metric tons per day with commissioning planned during FY2026-27.

Key Players in the Acetonitrile Market

Integrated Acetonitrile Producers

• INEOS Nitriles
• Ascend Performance Materials
• Balaji Amines Limited
• Alkyl Amines Chemicals Limited

Chromatography and Research-Chemical Channels

• Merck KGaA
• Solstice Advanced Materials
• Thermo Fisher Scientific

Application Development and Regional Supply

• Asahi Kasei Corporation

Acetonitrile Market - Report Scope

Coverage field	Report scope
Market breakdown	By product type, end user industry, and region.
Quantitative Units	USD million.
Market Definition	Commercial third-party sales of acetonitrile used as solvent or process material within the stated product grades and end user industries.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, and Middle East and Africa.
Countries Covered	Brazil, South Korea, Japan, United States, Germany, and 20+ countries included in the full report.
Key Companies Profiled	INEOS Nitriles, Ascend Performance Materials, Merck KGaA, Solstice Advanced Materials, Thermo Fisher Scientific, Asahi Kasei Corporation, Balaji Amines Limited, Alkyl Amines Chemicals Limited.
Forecast Period	2026 to 2036.
Approach	Primary and secondary research with market triangulation.

Acetonitrile Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Acetonitrile Market by Segments

Acetonitrile Market segmented by Product Type:

• Specialty Grade
• Laboratory Grade
• Industrial Grade

Acetonitrile Market segmented by End User Industry:

• Pharmaceuticals & Biotechnology
• Chemical Industry
• Laboratories & Analytical Services
• Electronics & Energy
• Others

Acetonitrile Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Merck KGaA / MilliporeSigma. (2026, April 21). MilliporeSigma Launches First Bio-Based Solvent Portfolio for HPLC.
• USA Food and Drug Administration. (2026, July). Novel Drug Approvals for 2025.
• Federal Institute for Drugs and Medical Devices. (2025, December 19). Marketable medicinal products in the responsibility of the BfArM.
• USA Food and Drug Administration. (2026, February). FY 2025 GDUFA Performance Report.
• Biocon Biologics Limited. (2025, July 16). Integrated Annual Report FY 2025.
• Asahi Kasei Corporation. (2025, November 4). Asahi Kasei licenses novel electrolyte technology to EAS Batteries for the market launch of an ultra-high power cell.
• Government of Brazil, Ministry of Health. (2026, July 20). Lei institui Estratégia Nacional de Saúde do Complexo Econômico-Industrial da Saúde.
• Government Performance Evaluation Portal, Republic of Korea. (2025, July 24). Innovative drug approvals through intensive support for innovative medicines.
• Pharmaceuticals and Medical Devices Agency. (2025, May). List of Approved Drugs: New Drugs Approved in May 2025.
• USA Food and Drug Administration. (2026, May). 2025 First Generic Drug Approvals.
• Federal Institute for Drugs and Medical Devices. (2025, November 30). Lieferengpässe.
• Asahi Kasei Corporation. (2026, August 6). Asahi Kasei Enters First License Agreement for Production and Sale of Acetolyte Novel Electrolyte in China.
• Asahi Kasei Corporation. (2025, May 27). Discontinuation of MMA, CHMA, PMMA resin, and SB latex businesses, and reconfiguration of acetonitrile supply framework.
• Asahi Kasei Corporation. (2026, June 2). EAS Batteries Starts Sales of Ultra-High-Power Cell Using Asahi Kasei’s Novel Electrolyte Acetolyte™.
• Ascend Performance Materials. (2026, February 4). Ascend cuts ribbon on new high-purity acetonitrile production.
• Balaji Amines Limited. (2025, June 26). Earnings call transcript, June 19, 2025.
• INEOS Group Holdings S.A. (2026, March 18). Annual Report 2025.
• Thermo Fisher Scientific. (2026, May 3). Certificate of Analysis: Acetonitrile, Optima LC-MS Grade.
• Thermo Fisher Scientific Inc. (2026, April 7). Annual Report 2025.
• Solstice Advanced Materials. (2025, September 30). Form 10-12B/A.
• Balaji Amines Limited. (2025, July 30). Annual Report 2024-25.
• Alkyl Amines Chemicals Limited. (2025, May 16). Transcript of earnings conference call held on May 12, 2025.
• Alkyl Amines Chemicals Limited. (2025, July 1). Summary of Proceedings of 45th Annual General Meeting.
• Balaji Amines Limited. (2026). Research & Development | Balaji Amines Annual Report 2026.
• Balaji Amines Limited. (2026, July 10). Proceedings of the 38th Annual General Meeting.
• Balaji Amines Limited. (2026). Balaji Amines Limited corporate profile. Retrieved August 20, 2026.
• INEOS. (2023, November 24). ISO 9001:2015 Certificate of Approval - Lima.
• Solstice Advanced Materials. (2025, October 30). Solstice Advanced Materials completes spin-off from Honeywell and begins trading on Nasdaq.
• Ascend Performance Materials. (2025, May 12). Ascend begins production of high-purity acrylonitrile.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations

This Report Answers

• How large is the acetonitrile market in 2026 and what value is projected by 2036?
• Which pharmaceutical and analytical workloads sustain demand for high-purity acetonitrile?
• Why does specialty grade hold the leading share within product type?
• Why does pharmaceuticals & biotechnology account for the largest end user share?
• How do solvent recovery and co-product economics affect merchant acetonitrile purchases?
• How do the five profiled country CAGRs differ from Brazil through Germany?
• Which companies control upstream supply and which compete through laboratory channels?
• What evidence supports the High, Medium, and Low Competitive Benchmarking ratings?
• Which recent company actions are changing acetonitrile production and application development?